SHILPAMEDNSEShilpa Medicare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 6 Feb, 2026 · 14:46 IST

Shilpa Medicare Q3 FY26: consol PAT Rs 44.6 cr, revenue up 28% YoY

Revenue Growth 20pctPat Growth 25pctResults RestatedExceptional ItemResults View source PDFExplain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.1%Reaction day
₹316.50
prior close
₹317.00
announcement price
In-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%+1.9% vs market
Pharmaceuticals peers, median of 159sector-0.6%+1.7% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.6
10m
+0.4
15m
-0.4
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.1-0.8+1.9-0.6+1.7
Next day
+5.2+1.8+3.4+1.1+4.1
2d
+7.1+2.8+4.3+1.7+5.5
3d
+4.6+2.3+2.3+1.3+3.3
4d
+2.1+1.8+0.3+0.5+1.6
5d
+3.0+0.3+2.8+0.0+3.0
1w
+4.6+0.5+4.1-0.2+4.8
15d
+6.0-2.5+8.5-2.7+8.7
1m
+4.6-6.3+10.9-4.6+9.2
2m
+23.9-8.0+31.8-7.4+31.2
3m
+39.3+8.3+31.1+2.6+36.8
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare Q3 FY26: consolidated revenue Rs 410.5 cr, up 28% YoY; PAT Rs 44.6 cr versus Rs 31.8 cr YoY. Standalone Q3 revenue Rs 177 cr, PAT Rs 15.9 cr. Exceptional loss of Rs 22 cr standalone and Rs 128.6 cr consolidated from new Labour Code gratuity impact and subsidiary impairments. Prior periods restated for INM Technologies merger. 1:1 bonus shares issued October 2025. Unmodified auditor review.

Likely market impact

Strong consolidated earnings growth aided by absence of prior year one-time charge; muted standalone shows mixed picture with restated comparables.